Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma  

作　　者：Rui-Xue Huo Ying-Ying Jin Yong-Xue Zhuo Xiao-Tong Ji Yu Cui Xiao-Jing Wu Yi-Jia Wang Long Zhang Wen-Hua Zhang Yu-Mei Cai Cheng-Cheng Zheng Rui-Xue Cui Qian-Ye Wang Zhen Sun Feng-Wei Wang 

机构地区：[1]Department of Oncology,Tianjin Union Medical Center,Tianjin 300000,China [2]School of Medicine,Nankai University,Tianjin 300000,China [3]Laboratory of Oncologic Molecular Medicine,Tianjin Union Medical Center,Tianjin 300000,China

出　　处：《World Journal of Clinical Cases》2022年第11期3414-3425,共12页世界临床病例杂志

基　　金：Supported by Tianjin Science and Technology Plan Project,No. 19YFZCSY00170;Tianjin Union Medical center,No. 2019YJ007;Beijing medical and health foundation,No. F1814B

摘　　要：BACKGROUND Patients with recurrent or locally advanced head and neck squamous cell carcinoma(HNSCC)typically have limited treatment options and poor prognosis.AIM To evaluate the efficacy and safety of two drugs with potent radio-sensitization properties including gemcitabine and nedaplatin as concurrent chemoradiotherapy regimens in treating HNSCC.METHODS This single-arm prospective study enrolled patients with HNSCC to receive gemcitabine on days 1 and 8 and nedaplatin on days 1 to 3 for 21 days.Intensitymodulated radiation therapy with a conventional fraction was delivered 5 days per week.Objective response rate(ORR),disease control rate,and toxicity were observed as primary endpoints.Overall survival(OS)and progression free survival were recorded and analyzed as secondary endpoints.RESULTS A total of 24 patients with HNSCC were enrolled.During the median 22.4-mo follow-up,both ORR and disease control rate were 100%.The one-year OS was 75%,and one-year progression-free survival(PFS)was 66.7%(median PFS was 15.1 mo).Recurrent HNSCC patients had a poorer prognosis than the treatment-naïve patients,and patients who achieved complete response had better survival than those in the PR group(all P<0.05).The most common grade 1-4(100%)or grade 3-4 toxicities(75%)were hematological,and the most common grade 3-4 non-hematological toxicity was mucositis in 17(71%)patients.CONCLUSION Gemcitabine plus nedaplatin with concurrent chemoradiotherapy is a therapeutic option for HNSCC with predictable tolerability.Considering the high adverse event rate,the optimized dose and schedule must be further explored.

关 键 词：CHEMORADIOTHERAPY GEMCITABINE NEDAPLATIN Head and neck cancer RECURRENT Locally advanced 

分 类 号：R739.91[医药卫生—肿瘤]